Gables Capital Management Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Gables Capital Management Inc.
- $195 Million
- Q3 2024
A detailed history of Gables Capital Management Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Gables Capital Management Inc. holds 427,251 shares of CPRX stock, worth $9.09 Million. This represents 4.36% of its overall portfolio holdings.
Number of Shares
427,251
Previous 432,210
1.15%
Holding current value
$9.09 Million
Previous $6.69 Million
26.87%
% of portfolio
4.36%
Previous 3.54%
Shares
27 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$398 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$171 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$133 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$121 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$64.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.19B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...